MNRI
MCID: MNN042
MIFTS: 51

Meningioma, Radiation-Induced (MNRI)

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningioma, Radiation-Induced

MalaCards integrated aliases for Meningioma, Radiation-Induced:

Name: Meningioma, Radiation-Induced 57 13
Radiation Induced Meningioma 20 71
Meningioma 58 71
Mnri 57 20
Meningioma, Benign, No Icd-O Subtype 71

Characteristics:

Orphanet epidemiological data:

58
meningioma
Prevalence: 1-9/100000 (United States),1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare endocrine diseases


External Ids:

OMIM® 57 606190
MESH via Orphanet 45 D008579
ICD10 via Orphanet 33 D32.9
UMLS via Orphanet 72 C0025286
Orphanet 58 ORPHA2495
MedGen 41 C1853554
UMLS 71 C0025286 C1762616 C1853554

Summaries for Meningioma, Radiation-Induced

MalaCards based summary : Meningioma, Radiation-Induced, also known as radiation induced meningioma, is related to spinal meningioma and optic nerve sheath meningioma. An important gene associated with Meningioma, Radiation-Induced is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are Gastric cancer and AMPK Enzyme Complex Pathway. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and cerebellum, and related phenotypes are seizures and nausea and vomiting

More information from OMIM: 606190

Related Diseases for Meningioma, Radiation-Induced

Diseases related to Meningioma, Radiation-Induced via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1046)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 32.3 TRAF7 SMARCE1 SMARCB1 NF2
2 optic nerve sheath meningioma 32.1 SMARCB1 NF2
3 secretory meningioma 32.1 TRAF7 SMARCE1 SMARCB1 NF2
4 fibrous meningioma 32.1 TRAF7 NF2
5 chordoid meningioma 32.0 TRAF7 NF2
6 olfactory groove meningioma 32.0 TRAF7 NF2
7 psammomatous meningioma 32.0 TRAF7 NF2
8 intraventricular meningioma 32.0 TRAF7 NF2
9 anterior cranial fossa meningioma 31.9 TRAF7 NF2
10 pediatric meningioma 31.9 TRAF7 NF2
11 meningothelial meningioma 31.8 TRAF7 SMARCE1 NF2
12 transitional meningioma 31.8 TRAF7 SMARCE1 NF2
13 brain meningioma 31.8 TRAF7 SMO NF2
14 rhabdoid meningioma 31.7 TRAF7 SMARCB1 NF2 BAP1
15 angiomatous meningioma 31.4 TRAF7 SMARCE1 NF2 BAP1
16 clear cell meningioma 31.4 TRAF7 SMARCE1 SMARCB1 NF2
17 skull base meningioma 31.3 TRAF7 SMO SMARCE1 NF2
18 benign meningioma 31.1 TRAF7 TERT SMARCE1 NF2
19 neurilemmoma 31.1 SMARCB1 NF2 AKT1
20 neurofibromatosis, type i 31.1 SMARCB1 NF2 AKT1
21 spinal canal and spinal cord meningioma 31.0 TRAF7 SMARCE1 SMARCB1 NF2
22 frontal convexity meningioma 30.9 TRAF7 TERT PIK3CA NF2
23 benign ependymoma 30.8 NF2 AKT1
24 monosomy 22 30.7 SMARCB1 NF2
25 meningioma, familial 30.5 TRAF7 TERT SUFU SMARCE1 SMARCB1 PIK3CA
26 brain cancer 29.9 SMARCB1 PIK3CA NF2 AKT1
27 sarcoma 29.8 SMARCB1 PIK3CA PDGFB NF2 AKT1
28 rhabdoid cancer 29.8 SMARCE1 SMARCB1 NF2
29 atypical teratoid rhabdoid tumor 29.7 SMARCE1 SMARCB1 NF2
30 tuberous sclerosis 29.7 PIK3CA NF2 AKT1
31 cowden syndrome 29.7 PIK3CA NF2 AKT1
32 corpus callosum lipoma 29.6 SMARCB1 NF2
33 gliosarcoma 29.3 TERT PIK3CA AKT1
34 thyroid gland follicular carcinoma 29.3 TERT PIK3CA AKT1
35 melanoma 29.2 TERT PIK3CA PDGFB NF2 BAP1 AKT1
36 gallbladder cancer 29.2 TERT PIK3CA AKT1
37 neurilemmomatosis 29.2 SUFU SMARCE1 SMARCB1 NF2
38 skin melanoma 29.0 TERT PIK3CA BAP1 AKT1
39 thyroid gland anaplastic carcinoma 29.0 TERT PIK3CA AKT1
40 basal cell carcinoma 29.0 TERT SUFU SMO BAP1
41 rhabdomyosarcoma 28.9 SUFU PIK3CA PDGFB AKT1
42 basal cell nevus syndrome 28.9 SUFU SMO SMARCB1 NF2 AKT1
43 cholangiocarcinoma 28.8 TERT PIK3CA AKT1
44 skull base cancer 28.8 TRAF7 SMO SMARCE1 NF2
45 melanoma, uveal 28.8 TERT PIK3CA NF2 BAP1 AKT1
46 medulloblastoma 28.4 TERT SUFU SMO SMARCB1 PIK3CA PDGFB
47 li-fraumeni syndrome 28.2 TERT SUFU SMARCB1 PIK3CA NF2 AKT1
48 skin carcinoma 28.1 TERT SUFU SMO PIK3CA BAP1 AKT1
49 lymphoplasmacyte-rich meningioma 11.7
50 intracranial meningioma 11.4

Graphical network of the top 20 diseases related to Meningioma, Radiation-Induced:



Diseases related to Meningioma, Radiation-Induced

Symptoms & Phenotypes for Meningioma, Radiation-Induced

Human phenotypes related to Meningioma, Radiation-Induced:

58 (show top 50) (show all 74)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 58 Frequent (79-30%)
2 nausea and vomiting 58 Frequent (79-30%)
3 neurological speech impairment 58 Very rare (<4-1%)
4 emotional lability 58 Very rare (<4-1%)
5 ataxia 58 Occasional (29-5%)
6 facial palsy 58 Occasional (29-5%)
7 hydrocephalus 58 Occasional (29-5%)
8 increased intracranial pressure 58 Occasional (29-5%)
9 blindness 58 Very rare (<4-1%)
10 cognitive impairment 58 Occasional (29-5%)
11 cranial nerve paralysis 58 Occasional (29-5%)
12 obesity 58 Occasional (29-5%)
13 hypogonadotrophic hypogonadism 58 Frequent (79-30%)
14 back pain 58 Very rare (<4-1%)
15 ophthalmoplegia 58 Occasional (29-5%)
16 neoplasm of the skin 58 Very rare (<4-1%)
17 proptosis 58 Very rare (<4-1%)
18 headache 58 Frequent (79-30%)
19 memory impairment 58 Occasional (29-5%)
20 abnormality of the sense of smell 58 Occasional (29-5%)
21 abnormal cerebellum morphology 58 Occasional (29-5%)
22 cerebral hemorrhage 58 Very rare (<4-1%)
23 syncope 58 Very rare (<4-1%)
24 impotence 58 Frequent (79-30%)
25 neurofibromas 58 Occasional (29-5%)
26 hemiparesis 58 Occasional (29-5%)
27 brain stem compression 58 Very rare (<4-1%)
28 trigeminal neuralgia 58 Occasional (29-5%)
29 tinnitus 58 Very rare (<4-1%)
30 focal-onset seizure 58 Frequent (79-30%)
31 decreased serum estradiol 58 Frequent (79-30%)
32 difficulty walking 58 Occasional (29-5%)
33 functional motor deficit 58 Occasional (29-5%)
34 oculomotor nerve palsy 58 Occasional (29-5%)
35 urinary incontinence 58 Very rare (<4-1%)
36 excessive daytime somnolence 58 Very rare (<4-1%)
37 pituitary hypothyroidism 58 Frequent (79-30%)
38 visual acuity test abnormality 58 Occasional (29-5%)
39 upper limb muscle weakness 58 Occasional (29-5%)
40 abnormality of the mediastinum 58 Very rare (<4-1%)
41 amenorrhea 58 Frequent (79-30%)
42 transient global amnesia 58 Very rare (<4-1%)
43 papilledema 58 Occasional (29-5%)
44 neoplasm of the tongue 58 Very rare (<4-1%)
45 lower limb muscle weakness 58 Occasional (29-5%)
46 decreased testosterone in males 58 Frequent (79-30%)
47 decreased circulating acth level 58 Frequent (79-30%)
48 prolactin deficiency 58 Occasional (29-5%)
49 secondary growth hormone deficiency 58 Frequent (79-30%)
50 bitemporal hemianopia 58 Frequent (79-30%)

Clinical features from OMIM®:

606190 (Updated 05-Mar-2021)

GenomeRNAi Phenotypes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.25 PIK3CA
2 Decreased viability GR00055-A-2 10.25 PIK3CA
3 Decreased viability GR00055-A-3 10.25 NF2
4 Decreased viability GR00221-A-1 10.25 AKT1 PIK3CA SMARCB1
5 Decreased viability GR00221-A-2 10.25 AKT1 PDGFB PIK3CA SMARCB1
6 Decreased viability GR00221-A-3 10.25 AKT1 PDGFB SMARCB1 NF2
7 Decreased viability GR00221-A-4 10.25 AKT1 PIK3CA
8 Decreased viability GR00240-S-1 10.25 PDGFB
9 Decreased viability GR00249-S 10.25 AKT1 SMARCB1 NF2
10 Decreased viability GR00381-A-1 10.25 SMARCB1
11 Decreased viability GR00386-A-1 10.25 PDGFB
12 Decreased viability GR00402-S-2 10.25 PDGFB PIK3CA
13 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Meningioma, Radiation-Induced:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.11 AKT1 BAP1 NF2 PDGFB PIK3CA SMARCB1
2 embryo MP:0005380 10.08 AKT1 BAP1 NF2 PDGFB PIK3CA SMARCB1
3 mortality/aging MP:0010768 10.07 AKT1 BAP1 NF2 PDGFB PIK3CA SMARCB1
4 integument MP:0010771 10.03 AKT1 BAP1 NF2 PDGFB PIK3CA SMARCB1
5 liver/biliary system MP:0005370 9.88 AKT1 NF2 PDGFB SMARCB1 SUFU TERT
6 muscle MP:0005369 9.8 AKT1 BAP1 PDGFB PIK3CA SMARCB1 SMO
7 neoplasm MP:0002006 9.8 AKT1 BAP1 NF2 PIK3CA SMARCB1 SUFU
8 reproductive system MP:0005389 9.7 AKT1 BAP1 NF2 PDGFB PIK3CA SMARCB1
9 respiratory system MP:0005388 9.5 AKT1 BAP1 NF2 PDGFB SMO SUFU
10 skeleton MP:0005390 9.17 AKT1 NF2 PIK3CA SMARCB1 SMO SUFU

Drugs & Therapeutics for Meningioma, Radiation-Induced

Drugs for Meningioma, Radiation-Induced (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3 Fibrin Tissue Adhesive Phase 4
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Antifibrinolytic Agents Phase 4
7
Cisatracurium Approved Phase 3 96946-41-7 62887
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
11
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
12
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
13
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
14
Aminolevulinic acid Approved Phase 3 106-60-5 137
15 Anesthetics Phase 3
16 Antihypertensive Agents Phase 3
17 Vasoconstrictor Agents Phase 3
18 Contraceptive Agents Phase 3
19 Contraceptives, Oral Phase 3
20 Contraceptives, Postcoital Phase 3
21 Progestins Phase 3
22 Dermatologic Agents Phase 3
23 Photosensitizing Agents Phase 3
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Hydroxyurea Approved Phase 2 127-07-1 3657
26
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
27
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
28
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
29
Verapamil Approved Phase 2 52-53-9 2520
30
Mesna Approved, Investigational Phase 2 3375-50-6 598
31
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
32
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
carbamide peroxide Approved Phase 2 124-43-6
35
nivolumab Approved Phase 2 946414-94-4
36
Ipilimumab Approved Phase 2 477202-00-9
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Pasireotide Approved Phase 2 396091-73-9 9941444
39
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
40
Bevacizumab Approved, Investigational Phase 2 216974-75-3
41
Ifosfamide Approved Phase 2 3778-73-2 3690
42
Vatalanib Investigational Phase 2 212141-54-3 151194
43
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 Cytochrome P-450 CYP3A Inhibitors Phase 2
46 Anti-Arrhythmia Agents Phase 2
47 interferons Phase 2
48 Interferon-alpha Phase 2
49 Interferon alpha-2 Phase 2
50 Iron-Dextran Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
10 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
13 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
14 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
15 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
16 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
17 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
18 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
19 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
20 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
21 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
22 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
23 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
24 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
25 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
26 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
27 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
28 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
29 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
30 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
31 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
35 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2
36 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
37 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
38 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
39 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
40 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
41 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
42 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
43 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
44 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
45 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
46 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
47 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
48 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
49 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2
50 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Active, not recruiting NCT01117844 Phase 1, Phase 2

Search NIH Clinical Center for Meningioma, Radiation-Induced

Genetic Tests for Meningioma, Radiation-Induced

Anatomical Context for Meningioma, Radiation-Induced

MalaCards organs/tissues related to Meningioma, Radiation-Induced:

40
Brain, Pituitary, Cerebellum, Spinal Cord, Endothelial, Hypothalamus, Tongue

Publications for Meningioma, Radiation-Induced

Articles related to Meningioma, Radiation-Induced:

(show top 50) (show all 68)
# Title Authors PMID Year
1
Cytogenetic study of six cases of radiation-induced meningiomas. 57
11376799 2001
2
Intracranial long-term complications of radiation therapy: an image-based review. 61
33392738 2021
3
Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. 61
32818240 2020
4
Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations. 61
32253706 2020
5
Molecular alterations in meningioma: prognostic and therapeutic perspectives. 61
32890025 2020
6
Pituitary carcinomas: review of the current literature and report of atypical case. 61
30836020 2020
7
Meningioma Screening With MRI in Childhood Leukemia Survivors Treated With Cranial Radiation. 61
30880270 2019
8
[A Rare Case of Radiation-Induced Meningioma that Occurred Only 3 Years and 6 Months after Radiation Therapy for Oligodendroglioma]. 61
29930213 2018
9
Quadruple Neoplasms following Radiation Therapy for Congenital Bilateral Retinoblastoma. 61
29344496 2017
10
Coexistence of Radiation-Induced Meningioma and Moyamoya Syndrome 10 Years after Irradiation against Medulloblastoma: a Case Report. 61
28960048 2017
11
Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. 61
28775249 2017
12
Sphenoid wing en plaque meningioma development following craniopharyngioma surgery and radiotherapy: Radiation-induced after three decades. 61
28761508 2017
13
Radiation-Induced Meningiomas: An Exhaustive Review of the Literature. 61
27713063 2017
14
Multiple meningiomas in a woman irradiated in utero. 61
27612673 2016
15
Meningioma after radiotherapy for malignancy. 61
27068012 2016
16
Secondary malignancy following radiotherapy for thyroid eye disease. 61
27601944 2016
17
[Surgical seeding of an anaplastic ependymoma]. 61
24317886 2013
18
A radiation-induced meningioma "cures" a complex dural arteriovenous fistula. 61
23765916 2013
19
Radiation-induced intracranial meningioma and multiple cavernomas. 61
24051144 2013
20
Factors affecting functional outcomes in long-term survivors of intracranial germinomas: a 20-year experience in a single institution. 61
23373627 2013
21
Tumor-to-tumor metastasis from pituitary carcinoma to radiation-induced meningioma. 61
22989053 2013
22
Metastatic olfactory neuroblastoma invading a radiation-induced meningioma. 61
21752653 2011
23
Intracranial ependymomas treated with radiotherapy: long-term results from a single institution. 61
20706771 2011
24
[Exacerbation of radiation induced meningioma due to hemorrhage after cerebral angiography: a case report]. 61
21270478 2011
25
Favorable outcomes of pediatric patients treated with radiotherapy to the central nervous system who develop radiation-induced meningiomas. 61
20418026 2011
26
Childhood radiation-associated atypical meningioma with novel complex rearrangements involving chromosomes 1 and 12. 61
19077038 2009
27
Stereotactic radiosurgery for radiation-induced meningiomas. 61
19240608 2009
28
Possible involvement of brain tumour stem cells in the emergence of a fast-growing malignant meningioma after surgical resection and radiotherapy of high-grade astrocytoma: case report and preliminary laboratory investigation. 61
19215696 2009
29
Radiation-induced meningioma concealed by shunt valve artifact: case report. 61
18424999 2008
30
Radiation-induced meningioma. 61
18447746 2008
31
Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood. 61
17190987 2007
32
[Radiation-induced meningioma]. 61
17057887 2006
33
Radiation induced meningioma with a short latent period following high dose cranial irradiation - case report and literature review. 61
16292489 2006
34
Intracranial meningiomas in children: report of 27 new cases and critical analysis of 440 cases reported in the literature. 61
16551450 2006
35
Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. 61
16193392 2005
36
[High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia]. 61
15773318 2005
37
High-dose radiation-induced meningioma in children - case report and critical review of the literature. 61
15744628 2005
38
High dose radiation induced meningioma. 61
15799195 2004
39
Immunohistochemical and molecular study of radiation-induced multiple meningiomas with pleural and pulmonary metastasis. 61
15315314 2004
40
Synchronous basal cell carcinoma and meningioma following cranial irradiation for a pilocytic astrocytoma. 61
12820764 2003
41
Radiation-induced meningioma: a descriptive study of 253 cases. 61
12450029 2002
42
[Update in radiation-induced neoplasms: genetic studies]. 61
11888858 2002
43
Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. 61
11668501 2001
44
Radiation-induced meningioma with a long latency period: a case report. 61
11511997 2001
45
The clavicle: a vulnerable bone in pediatric oncology. 61
11251162 2001
46
Radiation-induced meningioma: a distinct molecular genetic pattern? 61
10901233 2000
47
[Radiation-induced meningioma 20 years after operation and high-dose irradiation of an ependymoma]. 61
10356722 1999
48
Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. 61
9131026 1997
49
[Radiation-induced meningioma: the changing pattern of the disease]. 61
9153891 1997
50
Radiation-induced meningioma following radiation therapy for pituitary adenoma. Case report. 61
15096001 1996

Variations for Meningioma, Radiation-Induced

Expression for Meningioma, Radiation-Induced

Search GEO for disease gene expression data for Meningioma, Radiation-Induced.

Pathways for Meningioma, Radiation-Induced

Pathways related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.39 TERT SMARCE1 SMARCB1 PIK3CA AKT1
2
Show member pathways
12 SMARCE1 SMARCB1 AKT1
3
Show member pathways
11.99 SUFU SMO PIK3CA AKT1
4
Show member pathways
11.91 PIK3CA PDGFB AKT1
5 11.84 PIK3CA PDGFB AKT1
6 11.83 TERT SUFU SMO PIK3CA PDGFB AKT1
7 11.72 PDGFB NF2 AKT1
8
Show member pathways
11.46 TERT PIK3CA AKT1
9 11.43 SMARCE1 PIK3CA AKT1
10 11.31 PIK3CA PDGFB AKT1
11 11.1 PIK3CA AKT1
12 11.08 PIK3CA AKT1
13 11.08 SUFU SMO AKT1
14 11.06 PIK3CA AKT1
15 11.02 PIK3CA AKT1
16 11.01 PIK3CA AKT1
17
Show member pathways
10.98 TERT PIK3CA AKT1
18 10.95 PIK3CA AKT1
19 10.94 PIK3CA AKT1
20 10.93 PIK3CA PDGFB
21
Show member pathways
10.83 SUFU SMO
22 10.82 PIK3CA AKT1
23
Show member pathways
10.81 SMO PIK3CA AKT1
24 10.77 PIK3CA AKT1
25 10.51 PIK3CA PDGFB AKT1

GO Terms for Meningioma, Radiation-Induced

Cellular components related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 9.43 PIK3CA NF2 AKT1
2 SWI/SNF complex GO:0016514 9.16 SMARCE1 SMARCB1
3 nBAF complex GO:0071565 8.96 SMARCE1 SMARCB1
4 npBAF complex GO:0071564 8.62 SMARCE1 SMARCB1

Biological processes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.46 TERT PDGFB
2 positive regulation of nitric-oxide synthase activity GO:0051000 9.43 TERT AKT1
3 nucleosome disassembly GO:0006337 9.4 SMARCE1 SMARCB1
4 negative regulation of macroautophagy GO:0016242 9.37 PIK3CA AKT1
5 mammary gland epithelial cell differentiation GO:0060644 9.32 SMO AKT1
6 positive regulation of organ growth GO:0046622 9.26 SMO AKT1
7 negative regulation of gene expression GO:0010629 9.26 TERT SMO PDGFB AKT1
8 anoikis GO:0043276 9.16 PIK3CA AKT1
9 interleukin-18-mediated signaling pathway GO:0035655 8.62 PDGFB AKT1

Sources for Meningioma, Radiation-Induced

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....